Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
- by pulseRebiotix, a Ferring company, announced today that it has completed enrollment of the pivotal Phase 3 clinical trial for RBX2660, an investigational therapy…
pulseFerring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years
- by pulseFerring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW)…
pulse
- 1
- 2